RVL Pharmaceuticals plc
RVLP
Price:
$0.0282
Market Cap:
$3.14M
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.[Read more]
Industry
Biotechnology
IPO Date
2018-10-19
Stock Exchange
NASDAQ
Ticker
RVLP
The ROE as of September 2024 (TTM) for RVL Pharmaceuticals plc (RVLP) is -155.18%
According to RVL Pharmaceuticals plc’s latest financial reports and current stock price. The company's current ROE is -155.18%. This represents a change of 167.23% compared to the average of -58.07% of the last 4 quarters.
RVL Pharmaceuticals plc (RVLP) Historical ROE (quarterly & annually)
How has RVLP ROE performed in the past?
The mean historical ROE of RVL Pharmaceuticals plc over the last ten years is -84.07%. The current -155.18% ROE has changed 84.59% with respect to the historical average. Over the past ten years (40 quarters), RVLP's ROE was at its highest in in the June 2018 quarter at 1.40%. The ROE was at its lowest in in the June 2023 quarter at -146.32%.
Average
-84.07%
Median
-94.84%
Minimum
-236.17%
Maximum
-8.99%
RVL Pharmaceuticals plc (RVLP) ROE by Quarter and Year
Discovering the peaks and valleys of RVL Pharmaceuticals plc ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 726.50%
Maximum Annual ROE = -8.99%
Minimum Annual Increase = -59.84%
Minimum Annual ROE = -236.17%
| Year | ROE | Change |
|---|---|---|
| 2022 | -101.17% | -6.30% |
| 2021 | -107.97% | 13.84% |
| 2020 | -94.84% | -59.84% |
| 2019 | -236.17% | 726.50% |
| 2018 | -28.57% | 165.31% |
| 2017 | -10.77% | 19.80% |
RVL Pharmaceuticals plc (RVLP) Average ROE
How has RVLP ROE performed in the past?
The current ROE of RVL Pharmaceuticals plc (RVLP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-101.33%
5-year avg
-113.74%
10-year avg
-84.07%
RVL Pharmaceuticals plc (RVLP) ROE vs. Peers
How is RVLP’s ROE compared to its peers?
RVL Pharmaceuticals plc’s ROE is less than Molecular Partners AG (0%), greater than MediciNova, Inc. (-33.08%), greater than Anebulo Pharmaceuticals, Inc. (-13.37%), greater than Champions Oncology, Inc. (-122.97%), less than Cyteir Therapeutics, Inc. (1.48%), greater than Aerovate Therapeutics, Inc. (-23.13%), greater than Adagene Inc. (-83.65%), greater than Acrivon Therapeutics, Inc. Common Stock (-63.48%), greater than Rezolute, Inc. (-47.31%), greater than AN2 Therapeutics, Inc. (-60.90%), greater than PMV Pharmaceuticals, Inc. (-54.72%), greater than Eliem Therapeutics, Inc. (-21.96%), greater than HCW Biologics Inc. (-47.03%), greater than Sensei Biotherapeutics, Inc. (-385.90%), greater than NextCure, Inc. (-48.14%), greater than Nuvation Bio Inc. (-57.63%), greater than Graphite Bio, Inc. (-98.79%), greater than Merrimack Pharmaceuticals, Inc. (-57.96%), greater than null (-35.28%),
| Company | ROE | Market cap |
|---|---|---|
| 0% | $182.90M | |
| -33.08% | $103.00M | |
| -13.37% | $46.68M | |
| -122.97% | $57.77M | |
| 1.48% | $108.71M | |
| -23.13% | $54.85M | |
| -83.65% | $115.55M | |
| -63.48% | $250.26M | |
| -47.31% | $240.80M | |
| -60.90% | $30.44M | |
| -54.72% | $77.28M | |
| -21.96% | $495.57M | |
| -47.03% | $26.62M | |
| -385.90% | $15.32M | |
| -48.14% | $39.73M | |
| -57.63% | $692.60M | |
| -98.79% | $185.19M | |
| -57.96% | $223.97M | |
| -35.28% | $0 |
Build a custom stock screener for RVL Pharmaceuticals plc (RVLP) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like RVL Pharmaceuticals plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
RVL Pharmaceuticals plc (RVLP) and other stocks custom spreadsheet templates
The easiest way to analyze a company like RVL Pharmaceuticals plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is RVL Pharmaceuticals plc's ROE?
How is the ROE calculated for RVL Pharmaceuticals plc (RVLP)?
What is the highest ROE for RVL Pharmaceuticals plc (RVLP)?
What is the 3-year average ROE for RVL Pharmaceuticals plc (RVLP)?
What is the 5-year average ROE for RVL Pharmaceuticals plc (RVLP)?
How does the current ROE for RVL Pharmaceuticals plc (RVLP) compare to its historical average?